ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition
ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural Effusions and ICU Resources in patients undergoing Cardiac Surgery.”
NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access
NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function. This patient, along with 15 others treated to date under compassionate use protocols for severe tricuspid regurgitation, have received NCSI’s GATE™ tricuspid valved stent designed to lead to restored valvular function and improved quality of life.
Cleveland Clinic innovation team shares strategic formula for tech transformation
Wouldn’t you like a look inside the Cleveland Clinic’s innovation mindset? Attendees at the HIMSS and Health 2.0 Dev4Health event here this week got just such a glimpse.
ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons
ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018. Amongst key recommendations to promote enhanced patient outcomes after cardiac surgery is the use of Active Clearance techniques to maintain chest tube patency. The PleuraFlow® ACT® System is the only FDA cleared device with the indication to prevent or minimize retained blood in patients recovering from heart surgery.
Dev4Health conference examines how data sharing improves health care for patients, doctors
The health care industry is converging on ways for designers to create software that helps patients stay healthy and doctors deliver better and cheaper health care. It's a concept that's taking place at the Dev4Health conference downtown.
And let there be innovation!
Innovation in healthcare will bring with it innovation in the way healthcare is consumed and delivered. The emphasis on innovation will drive more efficient technology-enabled care models, integrated delivery designs which are tailor made to meet the specific needs of the patient.
2nd Annual Medical Capital Innovation Competition Winners Announced
BioEnterprise, in partnership with the Global Center for Health Innovation (Global Center), Cuyahoga County, and Healthcare Information and Management Systems Society (HIMSS) is pleased to announce the winners of the second annual Medical Capital Innovation Competition, “The Next Generation of Healthcare”:
28 Teams Chosen for 2nd Annual Medical Capital Innovation Competition
BioEnterprise, in partnership with the Global Center for Health Innovation (Global Center), Cuyahoga County, and Healthcare Information and Management Systems Society (HIMSS) is pleased to announce the participants of the second annual Medical Capital Innovation Competition (MCIC2) to be held at the Global Center for Health Innovation in Cleveland, April 23-24, 2018.
Cleveland Clinic Targets Telemedicine, Big Data and AI to Improve the Future of Care
The Cleveland Clinic has a history of being on the bleeding edge of health IT and its new CEO Tom Mihaljevic has made it clear that the Ohio-based health system will keep pushing ahead as a medical technology pioneer.
Boston Scientific Announces Acquisition of Securus Medical Group, Inc.
Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Securus Medical Group, Inc., a privately-held company that has developed a thermal monitoring system for the continuous measurement of esophageal temperature. Boston Scientific has been an investor in Securus since 2016, and the transaction price for the remaining stake not already owned consists of $40 million in cash up-front, as well as up to $10 million in contingent payments based on regulatory achievements and commercial milestones.